Pfizer and BioNTech have begun a clinical trial for their Omicron-specific COVID-19 vaccine candidate, they announced in a news release on Tuesday. The study will evaluate the vaccine for safety, ...

Upon authorization by the European Commission (EC), the Omicron KP.2-adapted COVID-19 vaccine will be available for individuals 6 months of age and older Data demonstrate that the Omicron KP.2-adapted ...

Pfizer will begin human trials of an omicron-specific COVID-19 vaccine beginning in late January, a company spokesperson confirmed Monday to FOX TV Stations. "We already have begun work on a DNA ...

Pfizer and BioNTech said Tuesday they've begun clinical trials for an omicron-based COVID-19 vaccine. According to a press release, the vaccine will be tested initially in adults aged 18 to 55. "While ...

Pfizer and BioNTech said Wednesday that initial lab tests show that the omicron variant partly escapes protection offered by the companies' two-dose regimen of their COVID-19 vaccine. However, those ...

The European Medicines Agency, the EU drug regulator, recommended that vaccine makers target the SARS-CoV-2 variant XFG when developing COVID-19 vaccines for the 2026/2027 immunization campaign. The ...

Pfizer and BioNTech are starting rolling applications with the U.S. Food and Drug Administration (FDA), per recent FDA recommendation, requesting approval of their Omicron KP.2-adapted monovalent ...

The updated COVID-19 vaccine is tailored to the Omicron JN.1 lineage of SARS-CoV-2 and is recommended for individuals 6 months of age and older Recommendation is based on pre-clinical and ...